"Our research and development initiatives have been a strong focus and point of investment in 2007 as we plan for Memry's future growth. These investments are helping us resume growth and we are beginning to see the benefits of our new capabilities and customer-sponsored development projects. We closed out our fiscal year 2007 with a number of accomplishments, such as the launch of our ultra small V2 tubing, our Putnam Plastics Plus (PPC+) product line that provides specialized secondary operations solutions for medical polymer tubing and our new customer-focused PPC+ website. I am extremely pleased to report that our emphasis on developing customer-sponsored research and development resulted in revenue of $5.1 million in fiscal year 2007, representing a three year compound annual growth rate of approximately 58% since 2004.
"For the year ended June 30, 2007, revenues for the nitinol products
segment decreased 3% or $1.0 million to $36.0 million from $37.0 million
during fiscal year 2006. This represented approximately 70% of consolidated
revenues in fiscal year 2007, similar to last year. The decrease was
primarily a result of price reductions granted for mature products in a
contract renewal, together with unit volume decreases experienced for older
generation stent components. We experienced revenue decreases for
superelastic nitinol tube, nitinol tube-based stent components, shipments
of Endocatch pr
'/>"/>
| SOURCE Memry Corporation Copyright©2007 PR Newswire. All rights reserved |